CASP9 genotype confers gentamicin susceptibility in intratympanic treatment of intractable vertigo caused by Ménière's disease. (3rd April 2019)

• Record Type: Journal Article
• Authors: Huang, Chi-Jung; Wan, Tan-Kuai; Fang, Te-Yung; Wang, Pa-Chun
• Is Part Of: Acta oto-laryngologica. Volume 139:Number 4(2019)
• Page Start: 336
• Page End: 339
• Publication Date: 2019-04-03
• Subjects: Ménière's disease -- intratympanic gentamicin treatment -- single nucleotide polymorphism -- caspase 9 -- cytochrome P450 2B6; Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.1080/00016489.2019.1575525
• Languages: English
• ISSNs: 0001-6489

Abstract

Abstract: Background: Ménière's disease (MD) is a disorder of the inner ear, causing episodes of vertigo. Although surgery is reserved for intractable MD, intratympanic gentamicin (ITG) injection has become an alternative for controlling vertigo. Aims/Objectives: To investigate the genetic basis of ITG efficacy. Material and methods: We hypothesized that single nucleotide polymorphisms (SNPs) affect outcomes in patients with MD who receive ITG injections. Whole-exome sequencing was used to determine variations in coding regions. Results: Multivariate analysis revealed two SNPs, rs1052571 in caspase 9 (CASP9; p = .017) and rs3745274 in cytochrome P450 2B6 ( p = .053), which were associated with susceptibility to ITG injections. Only the C-allele in the rs1052571 SNP was significantly associated with susceptibility ( p = .027; odds ratio: 5.95; 95% confidence interval: 1.26–28.57, by Fisher's exact test). Conclusions and significance: Our results elucidated the role of the rs1052571 SNP and provide a genetic perspective on gentamicin efficacy (susceptibility) in treating intractable MD.